Format

Send to

Choose Destination
Hum Gene Ther Methods. 2015 Jun;26(3):77-81. doi: 10.1089/hgtb.2015.086.

Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency.

Author information

1
1 Gene Therapy Center, University of Massachusetts Medical School , Worcester, MA 01655.
2
2 Department of Pediatrics, University of Massachusetts Medical School , Worcester, MA 01655.
3
3 Microbiology & Physiologic Systems, University of Massachusetts Medical School , Worcester, MA 01655.

Abstract

The pathway to a clinical gene therapy product often involves many changes of course and strategy before obtaining successful results. Here we outline the methodologies, both clinical and preclinical, that went into developing a gene therapy approach to the treatment of alpha-1 antitrypsin deficiency lung disease using muscle-targeted recombinant adeno-associated virus. From initial gene construct development in mouse models through multiple rounds of safety and biodistribution studies in rodents, rabbits, and nonhuman primates to ultimate human trials, this review seeks to provide insight into what clinical translation entails and could thereby inform the process for future investigators.

PMID:
26067712
PMCID:
PMC4559188
DOI:
10.1089/hgtb.2015.086
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center